Voriconazole and posaconazole therapy for experimental Candida lusitaniae infection

Marta Sanchis, Josep Guarro, Deanna A. Sutton, Annette W. Fothergill, Nathan Wiederhold, Javier Capilla

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


The in vitro activity of posaconazole (PSC) and voriconazole (VRC) was tested by using time-kill studies against 3 strains of Candida lusitaniae. Both drugs showed fungistatic activity against all strains. The efficacy of those compounds was evaluated by reducing kidney fungal burden and by determining (1→3)-β- d-glucan serum levels in a murine model of invasive infection of C. lusitaniae. The therapies tested were VRC at 10, 25, or 40. mg/kg/day and PSC at 5, 12.5, or 20. mg/kg/twice a day. All the dosages showed efficacy in a dose-dependant manner being high doses of both antifungals able to sterilize some kidneys after 10. days. With the exception of the strain FMR 9474, against which PSC was more effective than VRC, no differences in reducing tissue burden were found between the treatments. All doses of both antifungals were able to significantly reduce (1→3)-β- d-glucan serum levels with no significant differences between treatments and between the same doses of both drugs.

Original languageEnglish (US)
Pages (from-to)48-51
Number of pages4
JournalDiagnostic Microbiology and Infectious Disease
Issue number1
StatePublished - Jan 1 2016


  • Animal model
  • Antifungal
  • Candida lusitaniae
  • Fungal infections
  • Posaconazole
  • Voriconazole

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases


Dive into the research topics of 'Voriconazole and posaconazole therapy for experimental Candida lusitaniae infection'. Together they form a unique fingerprint.

Cite this